Comparative Pharmacology
Head-to-head clinical analysis: CHEWTADZY versus CIALIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHEWTADZY versus CIALIS.
CHEWTADZY vs CIALIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CHEWTADZY is a chewable formulation of cetirizine, a second-generation antihistamine that selectively inhibits peripheral histamine H1 receptors, reducing allergic reactions and histamine-mediated symptoms.
Phosphodiesterase-5 (PDE5) inhibitor; increases cGMP levels, causing smooth muscle relaxation and vasodilation in the corpus cavernosum, enhancing erectile function.
2 mg orally twice daily
Tadalafil 10 mg or 20 mg orally as needed at least 30 minutes before sexual activity; maximum dosing frequency once daily. Alternative: 2.5 mg or 5 mg once daily for daily use.
None Documented
None Documented
Terminal elimination half-life 12-15 hours, allowing once-daily dosing; prolonged in renal impairment (CrCl <30 mL/min)
The terminal elimination half-life of tadalafil is approximately 17.5 hours in healthy subjects, which supports once-daily dosing for erectile dysfunction and once-daily use for benign prostatic hyperplasia. This long half-life distinguishes it from other PDE5 inhibitors.
Primarily renal (55-65% unchanged), biliary/fecal (20-30%), with minor metabolism (<10%)
Following oral administration, tadalafil is predominantly eliminated by hepatic metabolism. The metabolites are excreted mainly in feces (approximately 61% of the dose) and to a lesser extent in urine (approximately 36% of the dose). No unchanged parent drug is detected in urine.
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor